Long-Term Obligations - Additional Information (Detail)
|
|
|
1 Months Ended |
3 Months Ended |
6 Months Ended |
|
|
|
|
May 13, 2024
USD ($)
shares
|
May 08, 2024
USD ($)
shares
|
May 31, 2024
USD ($)
shares
|
Sep. 30, 2019
USD ($)
|
Jun. 30, 2025
USD ($)
$ / shares
shares
|
Jun. 30, 2024
USD ($)
|
Jun. 30, 2025
USD ($)
Days
$ / shares
shares
|
Jun. 30, 2024
USD ($)
|
Dec. 31, 2024
USD ($)
|
Aug. 01, 2023
$ / shares
shares
|
Oct. 31, 2018
USD ($)
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Cash, cash equivalents and investments |
|
|
|
|
$ 51,700,000
|
|
$ 51,700,000
|
|
|
|
|
| Percentage of redemption fee |
|
|
|
|
|
|
3.00%
|
|
|
|
|
| Debt instrument exchange amount |
|
|
$ 148,000,000
|
|
|
|
|
|
|
|
|
| Exercise price | $ / shares |
|
|
|
|
$ 0.0001
|
|
$ 0.0001
|
|
|
|
|
| Gain on extinguishment of debt |
|
|
|
|
$ 0
|
$ 44,702,000
|
$ 0
|
$ 44,702,000
|
|
|
|
| Line of Credit [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Quarterly cash payments |
|
|
|
|
|
|
6.25%
|
|
|
|
|
| Secured Overnight Financing Rate [Member] | Line of Credit [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Rate margin |
|
|
|
|
|
|
9.25%
|
|
|
|
|
| Base Rate [Member] | Line of Credit [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Rate margin |
|
|
|
|
|
|
3.00%
|
|
|
|
|
| Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Prepayment premium |
|
|
|
|
|
|
5.00%
|
|
|
|
|
| Exercise price | $ / shares |
|
|
|
|
|
|
|
|
|
$ 33.75
|
|
| Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Prepayment premium |
|
|
|
|
|
|
3.00%
|
|
|
|
|
| Exercise price | $ / shares |
|
|
|
|
|
|
|
|
|
$ 16.5
|
|
| May 2024 Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Warrants purchased | shares |
|
3,100,000
|
|
|
3,100,000
|
|
3,100,000
|
|
|
|
|
| Exercise price | $ / shares |
|
|
|
|
$ 16.5
|
|
$ 16.5
|
|
|
|
|
| May 2024 Warrants [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Warrants purchased | shares |
3,100,000
|
|
3,100,000
|
|
|
|
|
|
|
|
|
| Percentage common stock outstanding |
|
|
|
|
19.99%
|
|
19.99%
|
|
|
|
|
| May 2024 Warrants [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Percentage common stock outstanding |
|
|
|
|
4.99%
|
|
4.99%
|
|
|
|
|
| Pre Funded Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Exercise price | $ / shares |
|
|
|
|
$ 0.0001
|
|
$ 0.0001
|
|
|
|
|
| Deferred Royalty Obligation [Member] | Level 3 [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Deferred royalty obligation at fair value |
|
|
|
|
$ 73,500,000
|
|
$ 73,500,000
|
|
$ 73,500,000
|
|
|
| HealthCare Royalty Partners IV LP [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Maximum remaining amount |
|
|
$ 128,300,000
|
|
|
|
|
|
|
|
|
| HealthCare Royalty Partners IV LP [Member] | Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Warrants purchased | shares |
|
|
|
|
|
|
|
|
|
16,667,000
|
|
| Revenue Interest Financing Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Debt issuance costs |
|
|
|
|
$ 1,700,000
|
|
$ 1,700,000
|
|
|
|
|
| First investment amount |
|
|
|
$ 135,000,000
|
|
|
|
|
|
|
|
| Aggregate Royalties |
|
|
|
$ 263,300,000
|
|
|
|
|
|
|
|
| Revenue Interest Financing Agreement [Member] | HealthCare Royalty Partners IV LP [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Repayment terms |
|
|
|
|
|
|
term may be shortened or extended depending on actual worldwide net product sales and upfront payments, milestones, and royalties. The repayment period expires on the earlier of (i) the date on which HCRx and KKR have received cash payments in the aggregate totaling $263.3 million or (ii) the legal maturity date of October 1, 2031. If HCRx and KKR have not received total payments in the aggregate equal to $263.3 million by October 1, 2031, we will be required to pay an amount equal to $135.0 million plus a specific annual rate of return less aggregate payments previously paid to HCRx and KKR. In the event of a change of control, an event of default, including, among others, our failure to pay any amounts due to KKR, insolvency, our failure to pay indebtedness when due, the revocation of regulatory approval of XPOVIO in the U.S. or our breach of any covenant contained in the Amended Revenue Interest Agreement and our failure to cure the breach within the prescribed time frame, we are obligated to pay KKR an amount equal to $263.3 million less aggregate payments previously paid to HCRx and KKR.
|
|
|
|
|
| Revenue Interest Financing Agreement [Member] | KKR & Co. Inc. [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Repayment terms |
|
|
|
|
|
|
term may be shortened or extended depending on actual worldwide net product sales and upfront payments, milestones, and royalties. The repayment period expires on the earlier of (i) the date on which HCRx and KKR have received cash payments in the aggregate totaling $263.3 million or (ii) the legal maturity date of October 1, 2031. If HCRx and KKR have not received total payments in the aggregate equal to $263.3 million by October 1, 2031, we will be required to pay an amount equal to $135.0 million plus a specific annual rate of return less aggregate payments previously paid to HCRx and KKR. In the event of a change of control, an event of default, including, among others, our failure to pay any amounts due to KKR, insolvency, our failure to pay indebtedness when due, the revocation of regulatory approval of XPOVIO in the U.S. or our breach of any covenant contained in the Amended Revenue Interest Agreement and our failure to cure the breach within the prescribed time frame, we are obligated to pay KKR an amount equal to $263.3 million less aggregate payments previously paid to HCRx and KKR.
|
|
|
|
|
| Amended Revenue Interest Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Aggregate principal amount |
|
|
135,000,000
|
|
|
|
|
|
|
|
|
| Revenue Interest Agreement and Amended Revenue Interest Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Debt instrument interest rate |
|
|
|
|
16.00%
|
|
16.00%
|
|
|
|
|
| Revenue Interest Agreement and Amended Revenue Interest Agreement [Member] | HealthCare Royalty Partners IV LP [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Cumulative payments |
|
|
49,500,000
|
|
$ 147,100,000
|
|
$ 147,100,000
|
|
|
|
|
| Convertible Note Offering [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Notes converted in to common stock, amount | shares |
|
|
|
|
|
|
4.2049
|
|
|
|
|
| Notes converted in to common stock, shares |
|
|
|
|
|
|
$ 1,000
|
|
|
|
|
| Notes, conversion price per share | $ / shares |
|
|
|
|
$ 237.82
|
|
$ 237.82
|
|
|
|
|
| Term Loan [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Aggregate principal amount |
|
|
15,000,000
|
|
|
|
|
|
|
|
|
| Debt issuance costs |
|
|
|
|
$ 6,800,000
|
|
$ 6,800,000
|
|
|
|
|
| Debt discount and issuance costs amortized to interest expense, amortization period |
|
|
|
|
|
|
4 years
|
|
|
|
|
| Expected life |
|
|
|
|
|
|
4 years
|
|
|
|
|
| Debt instrument interest rate |
|
|
|
|
16.83%
|
|
16.83%
|
|
|
|
|
| 6% Convertible Senior Notes Due 2029 [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Aggregate principal amount |
|
|
111,000,000
|
|
|
|
|
|
|
|
|
| 6% Convertible Senior Notes Due 2029 [Member] | HealthCare Royalty Partners IV LP [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Aggregate principal amount |
|
|
5,000,000
|
|
|
|
|
|
|
|
|
| Credit Agreement and Term Loan [Member] | Line of Credit [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Cash, cash equivalents and investments |
|
|
|
|
$ 25,000,000
|
|
$ 25,000,000
|
|
|
|
|
| Line of credit facility |
|
$ 100,000,000
|
|
|
|
|
|
|
|
|
|
| 2029 Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Aggregate principal amount |
$ 5,000,000
|
|
|
|
116,000,000
|
|
116,000,000
|
|
116,000,000
|
|
|
| Debt issuance costs |
|
|
|
|
4,981,000
|
|
$ 4,981,000
|
|
|
|
|
| Notes, interest rate |
|
|
|
|
|
|
6.00%
|
|
|
|
|
| Proceeds from convertible debt |
|
111,000,000
|
|
|
|
|
|
|
|
|
|
| Notes conversion price, percentage |
|
|
|
|
|
|
130.00%
|
|
|
|
|
| Notes instrument, trading days | Days |
|
|
|
|
|
|
20
|
|
|
|
|
| Debt instrument convertible threshold consecutive trading days | Days |
|
|
|
|
|
|
30
|
|
|
|
|
| Percentage of redeem notes at premium with proceeds |
|
|
|
|
|
|
101.00%
|
|
|
|
|
| Estimated fair value of convertible notes |
|
|
|
|
$ 73,900,000
|
|
$ 73,900,000
|
|
81,700,000
|
|
|
| Debt instrument interest rate |
|
|
|
|
26.97%
|
|
26.97%
|
|
|
|
|
| Gain on extinguishment of debt |
|
|
|
|
|
$ 44,700,000
|
|
|
|
|
|
| Initial fair value |
|
78,900,000
|
|
|
$ 4,008,000
|
|
$ 4,008,000
|
|
13,688,000
|
|
|
| Initial fair value adjustment |
|
$ 32,100,000
|
|
|
|
|
|
|
|
|
|
| Bifurcation of embedded derivatives |
|
|
|
|
$ 28,900,000
|
|
$ 28,900,000
|
|
|
|
|
| 2029 Notes [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Percentage common stock outstanding |
|
|
|
|
19.99%
|
|
19.99%
|
|
|
|
|
| 2029 Notes [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Cash, cash equivalents and investments |
|
|
|
|
$ 25,000,000
|
|
$ 25,000,000
|
|
|
|
|
| Percentage common stock outstanding |
|
|
|
|
4.99%
|
|
4.99%
|
|
|
|
|
| 2029 Notes [Member] | HealthCare Royalty Partners IV LP [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Aggregate principal amount |
5,000,000
|
|
|
|
|
|
|
|
|
|
|
| 2029 Notes [Member] | Convertible Note Offering [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Notes converted in to common stock, amount | shares |
|
|
|
|
|
|
29.6296
|
|
|
|
|
| Notes converted in to common stock, shares |
|
|
|
|
|
|
$ 1,000
|
|
|
|
|
| Proceeds from convertible debt |
|
|
|
|
|
|
$ 111,000,000
|
|
|
|
|
| Notes, conversion price per share | $ / shares |
|
|
|
|
$ 33.75
|
|
$ 33.75
|
|
|
|
|
| 2025 Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Aggregate principal amount |
|
|
$ 24,500,000
|
|
$ 24,500,000
|
|
$ 24,500,000
|
|
24,500,000
|
|
$ 172,500,000
|
| Debt issuance costs |
|
|
|
|
5,600,000
|
|
$ 5,600,000
|
|
|
|
|
| Debt discount and issuance costs amortized to interest expense, amortization period |
|
|
|
|
|
|
7 years
|
|
|
|
|
| Notes, interest rate |
|
|
|
|
|
|
3.00%
|
|
|
|
|
| Notes, maturity date |
|
|
|
|
|
|
Oct. 15, 2025
|
|
|
|
|
| Principal amount of notes used in conversion rate |
|
|
|
|
1,000
|
|
$ 1,000
|
|
|
|
|
| Debt instrument, convertible latest date |
|
|
|
|
|
|
Jul. 15, 2025
|
|
|
|
|
| Notes conversion price, percentage |
|
|
|
|
|
|
130.00%
|
|
|
|
|
| Notes instrument, trading days | Days |
|
|
|
|
|
|
20
|
|
|
|
|
| Debt instrument convertible threshold consecutive trading days | Days |
|
|
|
|
|
|
30
|
|
|
|
|
| Notes, repurchase price |
|
|
|
|
|
|
100.00%
|
|
|
|
|
| Estimated fair value of convertible notes |
|
|
|
|
$ 18,200,000
|
|
$ 18,200,000
|
|
$ 19,100,000
|
|
|
| Expected life |
|
|
|
|
|
|
7 years
|
|
|
|
|
| Debt instrument interest rate |
|
|
|
|
3.53%
|
|
3.53%
|
|
|
|
|
| 2025 Notes [Member] | Convertible Note Offering [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Notes converted in to common stock, shares |
$ 148,000,000
|
|
|
|
|
|
|
|
|
|
|